A B S T R A C T

Background. End-stage renal disease (ESRD) is associated with inflammation and increased reactive oxygen species (ROS).
Inflammation and oxidative stress are associated with several complications of ESRD. The aim of this study was to determine histological characteristics of adipose tissue and muscle mitochondrial function in uremia and its relationship with inflammation. Methods. ESRD patients (n ¼ 18) and controls (n ¼ 6) were enrolled for studies of adipose and muscle tissue by immunohistochemistry and western blot. In a uremic muscle cell model, C2C12 cells were exposed to uremic serum and inflammatory cytokines. Mitochondrial function was studied by MitoTracker Orange, translocase of the mitochondrial outer membrane 20 (TOMM20) and mitochondrial oxidative phosphorylation complex subunit expression. Results. ESRD patients had increased macrophage infiltration in subcutaneous and visceral adipose tissue compared with controls, even in nonobese ESRD patients (P < 0.05). Compared with controls, TOMM20 expression in muscle tissue was lower in ESRD, consistent with reduced mitochondrial function (P < 0.05). C2C12 exposed to uremia had decreased mitotracker intensity (P < 0.05) and the reduced mitochondrial function was rescued by N-acetyl cysteine (P < 0.01). Similarly, C2C12 cells exposed to tumor necrosis factor a (TNF-a)/interleukin-6 (IL-6) have decreased mitotracker intensity (P < 0.01) that was rescued with adiponectin (P < 0.05). C2C12 exposed to TNF-a, IL-6 and buthionine sulfoximine had decreased TOMM20 expression and cells exposed to TNF-a showed a decrease in subunits of mitochondrial complexes I and III. Conclusion. Our data indicate that uremia is associated with increased adipose tissue macrophage infiltration and concurrent muscle tissue mitochondrial dysfunction induced by inflammation/ROS. Adipose tissue is a potential source of inflammation in ESRD that is not due to increased adiposity and may contribute to mitochondrial dysfunction in uremia.
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I N T R O D U C T I O N
Despite a continued decline in the mortality rates among the end-stage renal disease (ESRD) population, patients on dialysis in their 30s-50s are expected to have a one-third reduction in their life expectancy compared with their counterparts without ESRD. Uremia, defined as the terminal clinical manifestation of ESRD, is also associated with increased morbidity [1] . The leading cause of death in ESRD is cardiovascular diseases, including heart failure, sudden cardiac death and atherosclerotic disease [2] . ESRD patients suffer from anemia, recurrent infections, bone disease, malnutrition and metabolic disorders. Muscle wasting is commonly associated with uremia, leading to insulin resistance and accelerated cardiovascular disease with increased mortality [3, 4] .
Uremic patients have high plasma levels of inflammatory markers [5, 6] . Systemic inflammation induces reactive oxygen species (ROS) [7, 8] and both systemic inflammation and ROS are associated with poor outcomes in patients with ESRD on hemodialysis (HD), peritoneal dialysis (PD) and in patients with chronic kidney disease (CKD) after transplantation [3, [9] [10] [11] [12] . Systemic inflammation and oxidative stress are involved in complications of uremia, including protein energy wasting [13] , anorexia [14] , anemia, vascular calcification [15] and endocrine disorders. Inflammation and ROS are also considered novel risk factors for cardiovascular disease [16, 17] . Although uremia is reversed to a large extent after kidney transplantation, there can be residual inflammation, although at a lower level [5] . The mechanisms by which kidney disease cause inflammation are not completely understood. Kidney disease is associated with many pro-inflammatory comorbidities, such as diabetes mellitus and congestive heart failure. Renal dysfunction impairs cytokine clearance [18] [19] [20] and decreases the production of suppressors of cytokine signaling [21] . Patients with CKD have reduced activity of the nuclear factor erythroid-2-related factor-2 (Nrf2) pathway, one of the main antioxidant pathways [22] . Recent reports suggest that altered gut microbiota in ESRD is also a possible factor that promotes inflammation [23] [24] [25] . In sum, multiple mechanisms have been proposed to explain why ESRD is a chronic inflammatory state.
Obesity is strongly associated with increased systemic inflammation independent of kidney disease, as adipose tissue is a major source of immune cell-derived inflammatory factors [26] . Adiponectin, an anti-inflammatory cytokine, is decreased in obesity with normal kidney function, secondary to decreased adiponectin production by the adipose tissue. Uremia alters adipose tissue metabolism with increased inflammatory cytokine production, and unlike obesity with normal kidney function, there is a marked increase in adiponectin production [5, 27] . In uremic patients, the altered adipokine balance plays a key role in the development of metabolic disturbances, persistent inflammation and accelerated atherosclerosis [28, 29] .
Uremia affects muscle function as well as adipose tissue metabolism. We previously demonstrated that alterations in muscle metabolism in uremia include adiponectin resistance at the post-receptor level [30] . Different factors have been associated with abnormal muscle metabolism in CKD models, including metabolic acidosis, angiotensin II, oxidative stress and inflammation. The purpose of this study was to determine if there is histological evidence of adipose tissue inflammation in ESRD that is independent of obesity and to determine if inflammation and/or ROS contribute to metabolic dysfunction in uremic muscle cells.
M A T E R I A L S A N D M E T H O D S
In this study we obtained adipose and muscle tissue samples in ESRD patients and controls with normal kidney function for histochemical analysis and protein analysis. To examine the effect of inflammation and ROS in muscle metabolism, we exposed C2C12 myoblast to different concentrations of uremic and normal serum and measured mitochondrial function.
Patients
Participants were recruited from the Thomas Jefferson University Hospital (TJUH) transplant program. The study protocol was approved by the Institutional Review Board at TJUH and written informed consent was obtained from each participant. Criteria for inclusion in the study included having ESRD and undergoing kidney transplantation at our institution. Patients with diabetes pre-kidney transplantation were excluded. The control group consisted of kidney donors with normal kidney function. While the participants were under general anesthesia for kidney donation or kidney transplantation, 250 mg of omental visceral fat, 250 mg of subcutaneous fat and 100 mg of skeletal muscle from the rectus abdominis were obtained.
Immunohistochemistry
Fixed adipose tissue samples were paraffin embedded. Paraffin-embedded sections of visceral and subcutaneous adipose tissue were immunostained as previously described [23] . Briefly, sections were deparaffinized, rehydrated and washed in phosphate-buffered saline (PBS). Antigen retrieval was performed in 10 mM sodium citrate, pH 6.0 for 10 min using a pressure cooker. Then, sections were blocked with 3% hydrogen peroxide for 10 min followed by incubation using an avidinbiotin blocking kit (Dako, Carpinteria, CA, USA) to block endogenous biotin. After incubation with 10% goat serum for 1 h, sections were incubated with primary antibodies overnight at 4 C (CD163, Ventana, Tucson, AZ, USA). Antibody binding was detected using a biotinylated secondary (Vector Labs, Burlingame, CA, USA) followed by strepavidin-HRP (Dako). Immunoreactivity was revealed using 3,3 0 -diaminobenzidine. Adipose tissue macrophage infiltration was measured as the number of CD163 þ cells in 10 randomly chosen 40Â areas (high power field) by two independent investigators. The number of CD163 þ cells was normalized by 100 adipocytes.
Western blot
A total of 50 mg of muscle from ESRD participants and from controls was homogenized with a bead beater in 400 mL of Laemmli buffer with protease and phosphatase inhibitors. The homogenate was spun at 1500 g for 10 min at 4 C and the upper layer was retrieved for protein quantification using the bicinchoninic acid assay (BCA) method (Thermo Scientific, Rockford, IL, USA). In all, 20 mg of the sample were mixed with 4X NuPAGE LDS sample buffer (Life Technologies, Grand Island, NY, USA) and mercaptoethanol and then loaded in a polyacrylamide gel (NuPAGE Novex 4-12% Bis-Tris gels, NuPAGE Tris-acetate 3-8% gels and Novex Tris-glycine 8-16%; Life Technologies) under reducing and heated conditions. Proteins were then transferred to a polyvinylidene fluoride membrane (Life Technologies). After transfer, membranes were blocked with 5% bovine serum albumin. Membranes were incubated with the primary antibody [translocase of the mitochondrial outer membrane 20 (TOMM20) and b-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), b-tubulin (Sigma); Mitoprofile total OXPHOS cocktail (Mitosciences, Eugene, OR, USA)] overnight at 4 C. Horseradish peroxidase conjugate secondary antibodies were incubated for 1 h and immunoreactivity for target proteins and controls was detected by an enhanced chemiluminescence system (SuperSignal West Dura Chemiluminescent Substrate; Thermo Scientific, Rockford, IL, USA). Experiments with different samples were repeated three times and representative images are presented.
Cell culture
C2C12 myoblasts were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 lg/mL streptomycin (Life Technologies). Cells were differentiated to myotubes for cytokines and mitotracker experiments by changing the growth media to DMEM and 2% horse serum (Gibco; Life Technologies) and grown for additional 3-5 days. After 6-24 h of exposure to uremic and normal serum, the cells were washed and lysed for western blot analysis with Laemmli buffer as previously described in the muscle immunoblotting section. Experiments were performed at least three times.
Mitochondrial activity in cell culture
C2C12 cells were stained with MitoTracker Orange (CMTMRos catalog #M7510, Invitrogen, Carlsbad, CA, USA), whose accumulation in mitochondria is dependent upon membrane potential. Briefly, C2C12 cells were incubated with prewarmed MitoTracker staining solution (diluted in serum-free DMEM to a final concentration of 10-35 nM) for 10 min at 37 C. All subsequent steps were performed in the dark. Cells were washed in PBS, harvested and resuspended in 500 mL of binding buffer (BD Biosciences, Franklin Lakes, NJ, USA). Cells were then analyzed by flow cytometry using a PE Texas Red signal detector with excitation wavelength of 496 nm and emission of 615 nm (to detect MitoTracker). Data analysis was performed using FlowJo 8.8 software (FlowJo, Ashland, OR, USA).
R E S U L T S
Baseline characteristics
Tissue studies were performed in 16 ESRD patients and 8 normal kidney function controls. Baseline characteristics are included in Table 1 . The cause of kidney disease was hypertension in seven patients (43%), glomerulonephritis in four patients (25%), polycystic kidney disease in three patients (19%) and other in two patients (12%). Half of the ESRD patients were pre-renal replacement therapy with a median creatinine of 4.65 mg/dL and median estimated glomerular filtration rate (eGFR) of 4.8 mL/ min. The median eGFR for the donor group was 119 mL/min. There were two participants undergoing PD and six patients undergoing HD at the time of kidney transplantation. Albumin concentration was similar in the ESRD and control groups (median 45 mg/L in controls and 43 mg/L in ESRD patients). None of the patients had hepatitis C and only one of the patients in the HD group had a prior kidney transplant.
Adipose tissue histology in ESRD
The histological characteristics of visceral and subcutaneous adipose tissue in ESRD patients and normal kidney function controls using the macrophage marker CD163 þ are presented in Figures 1 and 2 . Compared with controls, ESRD patients have increased macrophage infiltration in visceral ( Figure 1 ) and subcutaneous adipose tissue (Figure 2) . We also stratified patients and controls by their body mass index (BMI) as obese and nonobese. As shown in Figure 3 , the nonobese ESRD patients have increased macrophage infiltration in adipose tissue compared with controls. Obese ESRD patients appeared to have greater macrophage infiltration; however, the differences in macrophage infiltration between ESRD and controls did not reach statistical significance.
Mitochondrial function in human uremic muscle
Mitochondrial function in human muscle tissue of ESRD patients and controls was quantified by protein expression of TOMM20. TOMM20 is a subunit of TOMM complex, the main import pore for nuclear-encoded proteins to mitochondria, and is a protein associated with oxygen consumption rate, mitochondrial membrane potential and Cytochrome C oxidase activity [31] [32] [33] . TOMM20 also correlates with MitoTracker activity. By western blot analysis, TOMM20 protein expression in ESRD patients was significantly lower than in controls, as shown in Figure 4 (P < 0.05). These findings are consistent with impaired muscle cell mitochondrial metabolism in uremia.
Mitochondrial function in a cell model of uremic muscle
We used a cell model to further investigate mitochondrial dysfunction in uremia. We exposed the C2C12 myoblast cell line to different concentrations of uremic and normal human serum. Mitochondrial function in C2C12 muscle cells was measured by MitoTracker Orange. The nonfluorescent reduced form of MitoTracker Orange is oxidized by the molecular oxygen in actively respiring cells and therefore enables measurement of mitochondrial oxidative activity. As shown in Figure 5 , there is a decrease in MitoTracker activity in C2C12 cells exposed to uremic serum compared with cells exposed to normal serum ( Figure 5A ). The experiments were repeated with the antioxidant N-acetylcysteine (NAC) added to serum. The addition of NAC to normal serum did not change MitoTracker activity in C2C12 cells. However, in C2C12 cells, exposure to uremic serum plus NAC increased MitoTracker activity to levels similar to normal serum ( Figure 5B ). These results indicate that uremia alters mitochondrial function and that concurrent 
antioxidant exposure may be able to rescue uremia-mediated mitochondrial dysfunction.
To determine the role of inflammation in muscle mitochondrial dysfunction, we exposed C2C12 cells to ascending concentrations of TNF-a and IL-6 and determined mitochondrial activity by MitoTracker Orange. Figure 6 shows that mitochondrial activity decreases with increasing concentrations of TNF-a ( Figure 6A ) and IL-6 ( Figure 6B ). Exposure to both 2.8 fold TNF-a and the anti-inflammatory adiponectin results in an increase in mitochondrial function compared with cells exposed to TNF-a alone, although only at low TNF-a doses (1 ng/mL; Figure 6C ).
We also assessed TOMM20 protein expression of C2C12 exposed to TNF-a, IL-6 and the pro-oxidant buthionine sulfoximine (BSO). Similar to what was found in human muscle exposed to uremia, we demonstrated that TOMM20 protein expression decreases in C2C12 exposed to TNF-a, IL-6 and BSO (Figure 7) , suggesting the inflammatory cytokines and oxidants promote mitochondrial dysfunction. To further characterize the mitochondrial dysfunction, oxidative phosphorylation (OXPHOS) was determined by western blot analysis of five OXPHOS complexes with subunits that are labile when the respiratory chain complexes they belong to are not properly assembled. Thus, changes in expression levels of these subunits reflect alterations in the assembly of the respective complex. Figure 8 shows that the subunits of complex I and complex III are significantly decreased in C2C12 cells treated with high-dose TNF-a (10 ng/mL), suggesting that those complexes are somehow dysfunctional.
D I S C U S S I O N
Our study demonstrates increased macrophage infiltration in adipose tissue of uremic patients. Furthermore, there is increased CD163 þ cell infiltration in nonobese ESRD patients compared with BMI-matched controls. Our experiments on muscle tissue from uremic patients demonstrate mitochondrial dysfunction determined by lower expression of TOMM20 protein. To link the adipose histology with abnormal muscle metabolism, we used a cell model of uremic muscle. Following exposure of C2C12 cells to uremic serum, there was replication of mitochondrial dysfunction measured by MitoTracker Orange. When C2C12 cells were exposed to both uremia and NAC, a potent antioxidant, the uremia-mediated mitochondrial dysfunction was reversed. Mitochondrial dysfunction was also replicated by exposing C2C12 cells to the inflammatory cytokines TNF-a, IL-6 and the pro-oxidant BSO. Additionally, exposure to both TNF-a and the anti-inflammatory adiponectin was able to mitigate mitochondrial dysfunction, but only at lower TNF-a levels. Overall, our data suggest that inflammation and oxidative stress promote mitochondrial dysfunction in ESRD and that adipose tissue plays a contributing role in mediating uremic inflammation and metabolic stress.
The adipose tissue phenotype in obese patients has been extensively studied. Adipose tissue in obese patients is commonly infiltrated not only by macrophages and T cells, but also by B cells and mast cells [26, 34] . Both adipocytes and cells found in the stromal vascular fractions (SVFs) of the adipose tissue can produce inflammatory cytokines, but macrophages in the SVF are the most likely source of the increased inflammatory cytokine production in obesity [35] of obesity is also characterized by adipocyte hypertrophy, altered mitochondrial function, hypoxia, disruption of apoptotic signaling and endoplasmic reticulum (ER) stress [36, 37] . Consequently, within adipose tissue there is an increase in fatty acid release, increased production of ROS and altered adipokine signaling [38] , all of which are linked to metabolic dysfunction and disease. Overall, obesity alters the adipose tissue phenotype with inflammation, mitochondrial dysfunction, oxidative stress and ER stress. The role of adipose tissue in complications associated with uremia is controversial. There is a concept of reverse epidemiology of obesity in ESRD patients compared with the non-CKD population. Obese ESRD patients on dialysis have a survival advantage compared with nonobese ESRD patients [39, 40] . However, in a recent report, Stenvinkel et al. [41] provided evidence that inflammation modifies the relationship of obesity and mortality in ESRD patients. Their data demonstrated that at each BMI quintile the presence of inflammation increases mortality in ESRD patients. Higher BMI was associated with better outcomes just in the subset of dialysis patients with increased inflammation. These data are consistent with the concept that inflammation in ESRD patients is associated with excess morbidity. Obesity may reduce the detrimental FIGURE 5: MitoTracker Orange activity in C2C12 cells exposed to uremic and normal serum. (A) C2C12 cells were exposed to 2%, 5% and 10% of uremic serum for 6-24 h. Cells exposed to uremia show a decrease in MitoTracker activity with increasing concentrations, although there was no dose response (*P < 0.01, **P < 0.05). (B) C2C12 cells were exposed to 2% uremic and normal serum during 24 h 6 NAC 10 nM. Exposure to NAC was able to rescue MitoTracker activity in cells exposed to uremia (*P < 0.05). N: normal serum; U: uremic serum.
FIGURE 6: MitoTracker Orange activity in C2C12 cells exposed to different inflammatory cytokines and adiponectin. (A) C2C12 cells were exposed to TNF-a (0.1, 1 and 10 ng/mL) for 24 h and functional mitochondrial mass was assessed by MitoTracker Orange. Muscle cells exposed to increasing concentrations of TNF-a have decreased functional mitochondria. (B) C2C12 cells were exposed to IL-6 (0.01, 0.1 and 1 ng/mL) for 24 h and functional mitochondrial mass was assessed by MitoTracker Orange. Functional mitochondria are also decreased in muscle cells exposed to increasing concentrations of IL-6 (*P < 0.01). (C) C2C12 cells were exposed to ascending concentrations of TNF-a with or without globular adiponectin (1 mg/mL) and MitoTracker activity was measured. Muscle cells exposed to both TNF-a and adiponectin have increased functional mitochondrial, but only at lower TNF-a doses (**P < 0.05). consequences of increased inflammation in the dialysis population, but obesity was not associated with better outcomes in the noninflamed population. The association of adiponectin, the main adipose tissue anti-inflammatory cytokine, with outcomes in kidney disease is also not straightforward. Several studies have shown conflicting results, with some studies showing better outcomes with low and others with high adiponectin levels in CKD [28, 29, [42] [43] [44] [45] . Prior data have shown a nonlinear association between adiponectin and outcomes, suggesting the extremes in the higher and lower levels are both associated with mortality [45] . Similarly to BMI, it is possible that adiponectin's association with outcomes may be modulated by both protein energy wasting and fat mass and future studies are needed to provide more conclusive results.
Our histologic data demonstrate increased macrophage infiltration in adipose tissue of nonobese ESRD patients that is similar to that of obese patients with normal kidney function. Similarly, Axelsson et al. [46] also demonstrated an increase in the macrophage soluble marker CD163 in the peripheral blood of patients with kidney disease when compared with controls. Soluble CD163 values correlated with measures of fat mass, inflammation and endothelial adhesion molecules. Also, patients with soluble CD163 levels >4 mg/dL had worse outcomes. Moreover, we and others have previously described an increase in mRNA expression of inflammatory cytokines in adipose tissue of ESRD patients [27, 47] . Ramos et al. [48] reported that obesity amplifies the oxidative stress and inflammation that accompany moderate to severe CKD. These findings suggest a role of adipose tissue in the chronic inflammatory response to uremia. Our histological data refine the current knowledge by demonstrating direct macrophage infiltration in adipose tissue that is not driven by obesity alone, as it is present in nonobese uremic patients at higher levels than controls. The adipose tissue may then be an independent amplifier of the chronic inflammatory and oxidative state present in uremia and contribute to metabolic disease even in nonobese individuals [49] .
Uremia and inflammation affect muscle function as well as adipose tissue metabolism. Muscle wasting is common in ESRD patients and is associated with significant morbidity [41] . Mitochondrial biogenesis is a key component of skeletal muscle function and structure. Rao et al. [50] using mtDNA copy number as a surrogate of mitochondrial content, demonstrated lower mtDNA copy number in older dialysis patients, which was associated with greater mortality. In another study that used mitochondrial complex IV activity as a marker of overall mitochondrial function, Granata et al. [51] demonstrated reduced skeletal muscle mitochondrial activity in CKD patients. Alternatively, studies on response to resistance training in moderate to severe CKD patients report an increase in mtDNA copy number with exercise compared with controls [52] . There appears to be capacity to overcome some of the uremic effects on mitochondrial number. The findings in our study are consistent with these previous reports, as we demonstrate mitochondrial dysfunction by decreased TOMM20 expression in the muscle tissue of ESRD patients.
Experimental models of CKD also show changes in mitochondrial number and function. CKD decreases muscle mitochondrial mass and exercise endurance in a model of 5/6 nephrectomized mice [53] . Similarly, muscle samples from rats that have undergone 5/6 nephrectomy have impaired mitochondrial respiration, decreased mitochondrial mass, decreased energy production and increased ROS [54] . We also reproduced mitochondrial dysfunction by exposing muscle cells to uremic serum. C2C12 cells exposed to uremia present decreased functional mitochondria by MitoTracker Orange. Furthermore, we demonstrated that cells exposed to uremia and NAC were able recover mitochondrial function, suggesting ROS may play a role in the metabolic dysfunction seen in uremia. C2C12 exposure to TNF-a and IL-6 also resulted in decreased functional mitochondria, similar to prior work by Tamaki et al. [53] . These investigators exposed muscle cells to high levels of inflammatory cytokines and mediators of oxidative stress comparable to the levels seen in ESRD. Consistent with our findings, they demonstrated reduced expression of key genes of mitochondrial biogenesis [peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1a) and BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L)] and mitochondrial mass. In our study, addition of the anti-inflammatory cytokine adiponectin restored mitochondrial function in cells exposed to low concentrations of TNF-a, but not at high concentrations. Overall, our findings are consistent with developing evidence on the relationship of uremia and mitochondrial dysfunction. Uremia, via inflammation and/or ROS, promotes muscle metabolic dysfunction. Our findings in this study also suggest that anti-inflammatory and/or antioxidants can potentially reverse the mitochondrial dysfunction seen in uremic muscle.
Our study has some limitations. Our human tissue studies may have selected a somewhat healthier sample of ESRD patients, as they were all undergoing kidney transplantation, and they may have had a lesser degree of chronic inflammation. Adipose tissue changes seen in ESRD patients may not be generalizable to earlier CKD stages. The greater number of macrophages in ESRD adipose tissue implies greater inflammation; however, we did not identify the functional phenotype of the adipose tissue macrophages. Despite these limitations, our findings contribute novel insights on adipose tissue inflammation and muscle metabolic dysfunction in uremia.
In sum, our study suggests that the adipose tissue of nonobese ESRD patients contributes to uremic chronic inflammation and that inflammation and ROS play a role in mitochondrial dysfunction seen in uremia. Further studies are needed to delineate the mechanism of adipose tissue inflammation and mitochondrial dysfunction in uremia.
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